ATLANTA, GA--(Marketwire - July 12, 2012) - GeoVax Labs, Inc. (OTCQB: GOVX) (OTCBB: GOVX), an Atlanta-based biotechnology firm developing vaccines to prevent and treat Human Immunodeficiency Virus (HIV) infections, is presenting at the SeeThruEquity MicroCap Investor Forum taking place July 18 in New York City at The Cornell Club, located at 6 East 44th Street. Conference hours are 8:00 am - 5:00 pm. Registration information is available at www.seethruequity.com/content/forum/2012-07-18-forum.aspx.
The Company will present at 9:00 a.m. GeoVax's President and CEO, Dr. Robert McNally, and Mark Reynolds, Chief Financial Officer, will be available throughout the day to meet with interested parties to discuss the Company's preventive and therapeutic HIV/AIDS vaccine programs. To schedule a one-on-one meeting, please contact SeeThruEquity or IRG, LLC.
Dr. McNally said, "Meeting with potential investors in person gives us the chance to deliver the Company's message in a uniquely powerful way. We believe that East Coast investors will be extremely interested to hear about the clinical progress of our HIV vaccines and our plans for the remainder of 2012 and beyond."
After the conference, a recording of Dr. McNally's presentation will be available on GeoVax's website at www.geovax.com.
GeoVax Labs, Inc. is a biotechnology company developing human vaccines for HIV (Human Immunodeficiency Virus -- that leads to AIDS). GeoVax's HIV/AIDS vaccine technology is exclusively licensed from Emory University in Atlanta, GA, and is the subject of more than 20 issued or filed patent applications. GeoVax vaccines are designed for use in uninfected people to prevent acquisition of HIV-1 and limit the progression to AIDS should a person become infected. GeoVax vaccines are also being tested as a therapeutic treatment (for people already infected with the HIV-1 virus).
GeoVax's core vaccine technologies were developed by Dr. Harriet Robinson, Chief Scientific Officer, through a collaboration of colleagues at Emory University's Vaccine Center, the National Institute of Allergy and Infectious Diseases (NIAID), the Centers for Disease Control and Prevention (CDC) and GeoVax. The technology uses recombinant DNA to prime the immune response and recombinant modified vaccinia Ankara (MVA) to boost the primed response. Both the DNA vaccine and the MVA vaccine express non-infectious virus-like-particles displaying the natural trimeric form of the HIV envelope protein.
GeoVax's vaccines have moved forward in human clinical trials conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. These trials have tested various combinations and doses of the DNA and MVA vaccines, their ability to raise anti-HIV humoral (antibody) and cellular (cytotoxic T cell) immune responses, as well as, the vaccines' safety. Successful results from Phase 1 testing supported Phase 2a testing in an ongoing, fully enrolled, 299 participant trial in North and South America. The vaccine is also undergoing Phase 1/2 testing as a therapeutic in HIV-infected individuals.